Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial.

Infect Dis Ther · 2022 · PMC8847640 · PMID 34727366

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Although there was an increasing trend in incidence of AEs in subjects administered HS-10234 and emtricitabine, this may be related to higher HS-10234 and TFV-DP exposure.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.